These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Impact of visual impairment on measures of cognitive function for children with congenital toxoplasmosis: implications for compensatory intervention strategies. Roizen N; Kasza K; Karrison T; Mets M; Noble AG; Boyer K; Swisher C; Meier P; Remington J; Jalbrzikowski J; McLeod R; Kipp M; Rabiah P; Chamot D; Estes R; Cezar S; Mack D; Pfiffner L; Stein M; Danis B; Patel D; Hopkins J; Holfels E; Stein L; Withers S; Cameron A; Perkins J; Heydemann P Pediatrics; 2006 Aug; 118(2):e379-90. PubMed ID: 16864640 [TBL] [Abstract][Full Text] [Related]
6. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. McAuley J; Boyer KM; Patel D; Mets M; Swisher C; Roizen N; Wolters C; Stein L; Stein M; Schey W Clin Infect Dis; 1994 Jan; 18(1):38-72. PubMed ID: 8054436 [TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Bosch-Driessen LH; Verbraak FD; Suttorp-Schulten MS; van Ruyven RL; Klok AM; Hoyng CB; Rothova A Am J Ophthalmol; 2002 Jul; 134(1):34-40. PubMed ID: 12095805 [TBL] [Abstract][Full Text] [Related]
12. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Bosch-Driessen LE; Berendschot TT; Ongkosuwito JV; Rothova A Ophthalmology; 2002 May; 109(5):869-78. PubMed ID: 11986090 [TBL] [Abstract][Full Text] [Related]
13. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Soheilian M; Sadoughi MM; Ghajarnia M; Dehghan MH; Yazdani S; Behboudi H; Anisian A; Peyman GA Ophthalmology; 2005 Nov; 112(11):1876-82. PubMed ID: 16171866 [TBL] [Abstract][Full Text] [Related]
14. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Wallon M; Kodjikian L; Binquet C; Garweg J; Fleury J; Quantin C; Peyron F Pediatrics; 2004 Jun; 113(6):1567-72. PubMed ID: 15173475 [TBL] [Abstract][Full Text] [Related]
15. Imaging of congenital toxoplasmosis macular scars with optical coherence tomography. Garg S; Mets MB; Bearelly S; Mets R Retina; 2009 May; 29(5):631-7. PubMed ID: 19262439 [TBL] [Abstract][Full Text] [Related]
16. Ophthalmic outcomes after prenatal and postnatal treatment of congenital toxoplasmosis. Brézin AP; Thulliez P; Couvreur J; Nobré R; Mcleod R; Mets MB Am J Ophthalmol; 2003 Jun; 135(6):779-84. PubMed ID: 12788116 [TBL] [Abstract][Full Text] [Related]
18. Toxoplasmosis transmitted to a newborn from the mother infected 20 years earlier. Silveira C; Ferreira R; Muccioli C; Nussenblatt R; Belfort R Am J Ophthalmol; 2003 Aug; 136(2):370-1. PubMed ID: 12888070 [TBL] [Abstract][Full Text] [Related]
19. Ocular Toxoplasmosis in a Tertiary Referral Center in Sydney Australia-Clinical Features, Treatment, and Prognosis. Yates WB; Chiong F; Zagora S; Post JJ; Wakefield D; McCluskey P Asia Pac J Ophthalmol (Phila); 2019; 8(4):280-284. PubMed ID: 31369405 [TBL] [Abstract][Full Text] [Related]
20. The ocular manifestations of congenital infection: a study of the early effect and long-term outcome of maternally transmitted rubella and toxoplasmosis. O'Neill JF Trans Am Ophthalmol Soc; 1998; 96():813-79. PubMed ID: 10360309 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]